Comparison of Metformin and Myoinositol for the Treatment and Improvement of Clinical, Metabolic, and Hormonal Parameters in Women with Polycystic Ovary Syndrome

Uditi Merchant, Ashwini Desai

Abstract: The study demonstrates that treatment with both Metformin and Myoinositol improves clinical, hormonal, and metabolic profiles in women with polycystic ovary syndrome PCOS. After 6 months of therapy, both groups showed regular menstrual cycles, reduced mFG scores, decreased BMI, serum testosterone, LHFSH ratio, and improved polycystic ovarian morphology. Both drugs were found to be safe and effective in PCOS patients. When comparing the treatment groups, Myoinositol showed comparable efficacy to Metformin, except for a more significant decrease in serum testosterone levels by Metformin, reducing signs of hyperandrogenism. Myoinositolcan be considered as a viable treatment option for PCOS with comparable effectiveness. Myo - inositol may counteract the etiopathologies responsible for PCOS - related symptoms and serve as an alternative to treatments associated with side effects, particularly in adolescents

Keywords: Metformin, Myoinositol, insulin resistance

How to Cite?: Uditi Merchant, Ashwini Desai, "Comparison of Metformin and Myoinositol for the Treatment and Improvement of Clinical, Metabolic, and Hormonal Parameters in Women with Polycystic Ovary Syndrome", Volume 12 Issue 7, July 2023, International Journal of Science and Research (IJSR), Pages: 1228-1234, https://www.ijsr.net/getabstract.php?paperid=SR23717170358, DOI: https://dx.doi.org/10.21275/SR23717170358